Search

Search Constraints

You searched for: Author/Creator Izquierdo, Miguel

Search Results

1. A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab‐refractory iNHL (COMPLEMENT A + B study). (10th May 2021)

2. Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. (5th June 2018)

3. An open‐label, multicenter, efficacy, and safety study of deferasirox in iron‐overloaded patients with non‐transfusion‐dependent thalassemia (THETIS): 5‐year results. Issue 8 (27th May 2022)

4. Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex. Issue 6 (21st June 2022)

5. Crushed deferasirox film‐coated tablets in pediatric patients with transfusional hemosiderosis: Results from a single‐arm, interventional phase 4 study (MIMAS). Issue 8 (31st May 2022)

6. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. (30th April 2019)

7. Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension. Issue 4 (16th September 2022)

8. Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension. Issue 4 (16th September 2022)

9. Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B‐Cell Non‐Hodgkin's Lymphoma. Issue 9 (12th July 2022)

10. Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab. (5th July 2022)